Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-6)

Sum=68

Sep 5, 2025 (publication date) through Sep 4, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Pharmacology and Therapeutics

ISSN

2150-5349

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Systematic Reviews

World J Gastrointest Pharmacol Ther. Sep 5, 2025; 16(3): 110709
Published online Sep 5, 2025. doi: 10.4292/wjgpt.v16.i3.110709

Figure 1 PRISMA flowchart on study retrieval and inclusion in the meta-analysis.

Citation: Kamrul-Hasan ABM, Borozan S, Jena S, Nagendra L, Dutta D, Bhattacharya S, Islam MS, Pappachan JM. Safety and efficacy of efruxifermin in metabolic dysfunction-associated steatohepatitis: A systematic review. World J Gastrointest Pharmacol Ther 2025; 16(3): 110709
URL: https://www.wjgnet.com/2150-5349/full/v16/i3/110709.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v16.i3.110709